November 17, 2026 | Insights, metabolic care, real-world evidence
Metabolic medicine is changing faster than the evidence systems built to track it. New therapies for type 2 diabetes and obesity are reaching more patients, across more indications and through more channels than ever before. For HEOR and Medical Affairs teams, that raises a pressing question: how do you build a credible picture of real-world value when so much of what matters never reaches a database?
Real-world evidence (RWE) is central to the answer. Regulators, health technology assessment (HTA) bodies, and payers increasingly expect it. But in the broad metabolic space, generating RWE that is truly decision-grade is harder than it looks.

Structured data tell you what happened, but they don’t often tell you why, which is why primary research is crucial for developing an effective RWE strategy: not as a substitute for claims, EHR or registry data, but as the layer that provides the data that those areas do not. For HEOR or Medical Affairs, it can give strategic direction in five ways.
Some of the most consequential moments in metabolic care happen in the office between the patient and the HCP. How are treatment options presented? How are weight, side effects and long-term commitment discussed? What do patients take away? Is there shared decision making? These conversations shape initiation and persistence, yet routine data collection approaches almost never capture them.
KJT’s DialogueDx methodology is designed to close that gap. It captures authentic patient–provider conversations through in-office observation, then builds on them with patient video diaries, provider interviews and quantitative validation. Generative AI is used to analyse these interactions at scale.
Because it observes real conversations rather than relying on recall or separate participant interviews or surveys, DialogueDx gives teams a real-world view of where communication supports or undermines treatment goals, from the first prescribing discussion to the conversations that come before discontinuation. Those insights can sharpen evidence priorities, empower patients with appropriate questions to ask, inform HCP education and scientific communication, and point observational studies towards the questions that matter most.
The value comes from integration. Primary research can generate important real-world evidence when it is designed as part of the wider evidence plan, uses consistent definitions across data sources and studies, and informs both study design and field medical engagement. Its contribution is strongest when considered alongside other RWE sources, with appropriate attention to sample design, context, and the limitations inherent in observational evidence.
Metabolic care will remain one of the most scrutinised therapy areas for years to come. The Medical Affairs teams that make the strongest case for value will be those that combine what the data can measure with what only patients and HCPs can explain.
[1] Suissa K, Schneeweiss S, Lin KJ, Brill G, Kim SC, Patorno E. Validation of obesity-related diagnosis codes in claims data. Diabetes Obes Metab. 2021 Dec;23(12):2623-2631. doi: 10.1111/dom.14512. Epub 2021 Aug 18. PMID: 34338404; PMCID: PMC8578343 https://pubmed.ncbi.nlm.nih.gov/34338404/
[2]Xie L, Anazco D, Chancay AH, et al. Glucagon-Like Peptide-1 Receptor Agonist Switching and Treatment Persistence in Adults Without Diabetes. JAMA Netw Open. 2026;9(3):e261272. doi:10.1001/jamanetworkopen.2026.1272 – https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2846157
Dziewierz A, Siudak Z. Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support-A Narrative Review. Nutrients. 2026 May 30;18(11):1761. doi: 10.3390/nu18111761. PMID: 42280404; PMCID: PMC13259006 – https://pmc.ncbi.nlm.nih.gov/articles/PMC13259006
For more information visit: https://kjtgroup.com/solutions/commercial-solutions/dialoguedx/
Author: Danny Wolin, Real-world Evidence SVP
This content was provided by KJT Group